<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154930</url>
  </required_header>
  <id_info>
    <org_study_id>43USTT1904</org_study_id>
    <nct_id>NCT04154930</nct_id>
  </id_info>
  <brief_title>Restylane-L for Correction of Infraorbital Hollows</brief_title>
  <official_title>A Randomized, Evaluator-blinded, Parallel Group, No-treatment Controlled, Multi-center Study to Evaluate the Safety and Effectiveness of Restylane-L速 for Correction of Infraorbital Hollows</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, evaluator-blinded, no-treatment controlled, parallel
      group, multi-center US study to evaluate the safety and effectiveness of Restylane-L速 for
      correction of Infraorbital Hollows.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Galderma Infraorbital Hollows Scale (GIHS)</measure>
    <time_frame>3 months after baseline</time_frame>
    <description>At least 1 point improvement from baseline, on both sides of the face concurrently, on the Blinded Evaluators' live assessment of the Galderma Infraorbital Hollows Scale (GIHS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Infraorbital Hollows</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Restylane-L速 injected with optional touch at 1 month and optional retreatment at 12 months
,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment control with optional treatment at 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane-L速</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate or severe infraorbital hollows with no more than one grade difference between
             the left and right side at baseline as assessed by the blinded evaluator.

          -  Males or non-pregnant, non-breastfeeding females, over the age of 21.

          -  Intent to undergo correction of both orbital hollows.

        Exclusion Criteria:

          -  Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel
             or to gram positive bacterial proteins.

          -  Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or
             other amide-type anesthetics.

          -  Previous deep and/or superficial facial dermal therapies.

          -  Active or a history of recurrent or chronic infraorbital edema or rosacea or
             uncontrolled severe seasonal allergies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>817-961-5655</phone>
    <email>acrestylaneteartrough@advancedclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <zip>77388</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tear Trough</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

